Professor Andrew Coats MBA, DSc, DM, co-founded Actimed Therapeutics in 2017, having  previously founded Myotec (later renamed PsiOxus Therapeutics). Andrew has over 30 years of experience as an academic manager, having been both Dean of Medicine and Deputy Vice-Chancellor at the University of Sydney and head of Clinical Cardiology at Imperial College and the Royal Brompton Hospital in London. Andrew also served as CEO of the Norwich Research Park in the UK. Andrew is an experienced board director and chairman with an MBA from London Business School. He has over 20 years of experience of company boards in roles including audit, remuneration, nominations and governance committees in biotechnology, publishing health care and education, including the George Institute of International Health, the Woolcock Institute, Lone Star Heart, Myotec, PsiOxus, Radcliffe Group, ESN Cleer and Faraday (Australia). Andrew has been on the board of the Heart Failure Association (HFA) of the ESC since 2012 and will be its President from 2020 to 2022.  He has been a member of over 20 international clinical trial steering committees in the fields of heart failure and cachexia and has over 700 career research papers, 95,000 citations and an h-Index of 130.

Professor Stefan Anker MD, PhD, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). Stefan has 25 years academic research experience in heart failure, cachexia and clinical trials with positions at Royal Brompton Hospital and Imperial College in London as well as University Göttingen and Charité Berlin. Stefan has been a tenured University-Professor in Germany since 2007, leading a highly active research group, and he is founding Editor-in-Chief of two successful scientific journals (including the Journal of Cachexia, Sarcopenia and Muscle).  Stefan was Vice President of the European Society of Cardiology (ESC) from 2016 to 2018, and served on the ESC board from 2012 to 2018. He has served on the board of the Heart Failure Association (HFA) of the ESC since 2006; and was HFA President from 2012 to 2014.

Stefan is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders, a position that he has held since 2008 (see www.cachexia.org). Stefan has been and is a member of over 30 international clinical trial steering committees and is currently chairing or co-chairing 6 trials in phase II/ III/IV. In this context, Stefan has significant experience interacting with regulators in different branches of the FDA and EMA. Stefan has over 900 research papers, 118,000 citations and a h-Index of 142.

Yann Colardelle is a professional in communications and medical education who has been involved in research and education in cachexia for more than 15 years. In 1998 he founded Medical Education Global Solutions, a leading independent medical education company with a focus on global and multidisciplinary projects.

Yann holds a degree from the University of Provence and an eMBA at Paris Dauphine.  As a founder, he envisions Actimed therapeutics as the organisation that will change the paradigm of cachexia management and improve the lives of patients and their families and carers.